Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin Versus Ezetimibe Added-on to Rosuvastatin Versus Rosuvastatin Dose Increase in Patients Who Are Not Controlled on Rosuvastatin
Brief Summary: To evaluate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab (REGN727/SAR236553) as an add-on therapy to other LMT in patients with hypercholesterolemia at high cardiovascular (CV) risk.


Options:
A: Arm Label: Rosuvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: Placebo | Arm Label: Ezetimibe 10 mg + Rosuvastatin 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Rosuvastatin, Drug: Placebo | Arm Label: Rosuvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: Placebo | Arm Label: Ezetimibe 10 mg + Rosuvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Rosuvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg, Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg, Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg, Ezetimibe 10 mg + Rosuvastatin 10 mg, Ezetimibe 10 mg + Rosuvastatin 20 mg, Rosuvastatin 20 mg, Rosuvastatin 40 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg + Rosuvastatin 10 mg, Ezetimibe 10 mg + Rosuvastatin 20 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg, Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg, Ezetimibe 10 mg + Rosuvastatin 10 mg, Ezetimibe 10 mg + Rosuvastatin 20 mg, Rosuvastatin 20 mg, Rosuvastatin 40 mg
B: Arm Label: Alirocumab 75 /up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for ezetimibe), Drug: Lipid Modifying Therapy (LMT) | Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Ezetimibe, Drug: Lipid Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for ezetimibe); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W, Ezetimibe 10 mg
C: Arm Label: Group 1 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 2 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 3 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 4 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 5 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 6 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 7 without atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 8 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Intervention Type: DRUG; Name: REGN727(SAR236553); Assigned to Arm(s): Group 1 with atorvastatin, Group 2 with atorvastatin, Group 3 with atorvastatin, Group 4 with atorvastatin, Group 5 with atorvastatin, Group 6 with atorvastatin, Group 7 without atorvastatin, Group 8 with atorvastatin
D: Arm Label: Atorvastatin (statin rechallenge arm); Type: OTHER; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/ up to 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin (statin rechallenge arm) | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg, Atorvastatin (statin rechallenge arm), Ezetimibe

Answer: A